GUR-501 novel drug for asthma, COPD and COVID-19 pneumonia

First-in-class

First-in-class molecule

GUR-501 is first-in-class innovative drug candidate generated by our Prostaglandin & Nitric Oxide research platform for the treatment of asthma, COPD and COVID-19 pneumonia. This molecule is prostaglandin E2 (PGE2) modified by unique Nitric Oxide donor.

New set of targets

  • EP4 receptor for PGЕ2
  • EP2 receptor for PGЕ2
  • Soluble guanylyl cyclase for NO-releasing moiety.

Mechanism of action

GUR 501 relaxes the smooth muscles of the bronchi and has a pronounced anti-inflammatory effect in the lung tissue.

The only effective drug for chronic patients

Chronical patients lose receptor sensitivity to existing Asthma and COPD medications due to very long-term use of these drugs. As our molecule is endogenous, its efficiency does not drop with long term use. So, GUR-501 can be the only effective drug for those patients who lost a therapeutic response to the existing bronchodilators.

Advantages for COVID-19 pneumonia

- Strong anti-inflammatory activity in the lung tissue
- Neutrophilic activity suppression in the lung tissue
- Cytokine storm suppression in the lung tissue
- Clot formation prevention in the lung vessels